Evaxion Biotech Reports Q2 2025 Financial Results with Notable Losses

Evaxion Biotech ( (EVAX) ) has provided an announcement.

Evaxion Biotech A/S reported its financial results for the fiscal quarter ended June 30, 2025, showing a net loss of $4.831 million for the three months and $6.411 million for the six months. Despite the losses, the company experienced a positive exchange rate impact, contributing to a reduced comprehensive loss. This financial update is crucial for stakeholders as it highlights the company’s ongoing financial challenges amidst its innovative endeavors in the biotech sector.

The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall stock score is influenced primarily by its financial instability despite strong revenue growth. The positive sentiment from the earnings call and technical indicators provide some balance, but the negative valuation and financial challenges weigh heavily on the score.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion Biotech A/S is a Danish company operating in the biotechnology industry, primarily focused on developing AI-driven immunotherapies for cancer and infectious diseases.

Average Trading Volume: 115,065

Technical Sentiment Signal: Sell

Current Market Cap: $4M

See more insights into EVAX stock on TipRanks’ Stock Analysis page.